298 related articles for article (PubMed ID: 12964065)
1. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography.
Dufresne TE; Chmielewski PA; Manhart MD; Johnson TD; Borah B
Calcif Tissue Int; 2003 Nov; 73(5):423-32. PubMed ID: 12964065
[TBL] [Abstract][Full Text] [Related]
2. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography.
Borah B; Dufresne TE; Chmielewski PA; Johnson TD; Chines A; Manhart MD
Bone; 2004 Apr; 34(4):736-46. PubMed ID: 15050906
[TBL] [Abstract][Full Text] [Related]
3. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
[TBL] [Abstract][Full Text] [Related]
4. Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography.
Borah B; Dufresne TE; Chmielewski PA; Gross GJ; Prenger MC; Phipps RJ
J Bone Miner Res; 2002 Jul; 17(7):1139-47. PubMed ID: 12096826
[TBL] [Abstract][Full Text] [Related]
5. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.
Durchschlag E; Paschalis EP; Zoehrer R; Roschger P; Fratzl P; Recker R; Phipps R; Klaushofer K
J Bone Miner Res; 2006 Oct; 21(10):1581-90. PubMed ID: 16995813
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study.
Delmas PD; Balena R; Confravreux E; Hardouin C; Hardy P; Bremond A
J Clin Oncol; 1997 Mar; 15(3):955-62. PubMed ID: 9060533
[TBL] [Abstract][Full Text] [Related]
7. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up.
Mortensen L; Charles P; Bekker PJ; Digennaro J; Johnston CC
J Clin Endocrinol Metab; 1998 Feb; 83(2):396-402. PubMed ID: 9467547
[TBL] [Abstract][Full Text] [Related]
8. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography.
Borah B; Dufresne TE; Ritman EL; Jorgensen SM; Liu S; Chmielewski PA; Phipps RJ; Zhou X; Sibonga JD; Turner RT
Bone; 2006 Aug; 39(2):345-52. PubMed ID: 16571382
[TBL] [Abstract][Full Text] [Related]
9. The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover.
Borah B; Ritman EL; Dufresne TE; Jorgensen SM; Liu S; Sacha J; Phipps RJ; Turner RT
Bone; 2005 Jul; 37(1):1-9. PubMed ID: 15894527
[TBL] [Abstract][Full Text] [Related]
10. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.
Eastell R; Barton I; Hannon RA; Chines A; Garnero P; Delmas PD
J Bone Miner Res; 2003 Jun; 18(6):1051-6. PubMed ID: 12817758
[TBL] [Abstract][Full Text] [Related]
11. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients.
Eastell R; Devogelaer JP; Peel NF; Chines AA; Bax DE; Sacco-Gibson N; Nagant de Deuxchaisnes C; Russell RG
Osteoporos Int; 2000; 11(4):331-7. PubMed ID: 10928223
[TBL] [Abstract][Full Text] [Related]
12. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
[TBL] [Abstract][Full Text] [Related]
13. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis.
Ste-Marie LG; Sod E; Johnson T; Chines A
Calcif Tissue Int; 2004 Dec; 75(6):469-76. PubMed ID: 15478000
[TBL] [Abstract][Full Text] [Related]
14. Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women.
Zoehrer R; Roschger P; Paschalis EP; Hofstaetter JG; Durchschlag E; Fratzl P; Phipps R; Klaushofer K
J Bone Miner Res; 2006 Jul; 21(7):1106-12. PubMed ID: 16813531
[TBL] [Abstract][Full Text] [Related]
15. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.
Reid DM; Adami S; Devogelaer JP; Chines AA
Calcif Tissue Int; 2001 Oct; 69(4):242-7. PubMed ID: 11730260
[TBL] [Abstract][Full Text] [Related]
16. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk.
Watts NB; Cooper C; Lindsay R; Eastell R; Manhart MD; Barton IP; van Staa TP; Adachi JD
J Clin Densitom; 2004; 7(3):255-61. PubMed ID: 15319494
[TBL] [Abstract][Full Text] [Related]
17. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
van Bodegraven AA; Bravenboer N; Witte BI; Dijkstra G; van der Woude CJ; Stokkers PC; Russel MG; Oldenburg B; Pierik M; Roos JC; van Hogezand RA; Dik VK; Oostlander AE; Netelenbos JC; van de Langerijt L; Hommes DW; Lips P;
Gut; 2014 Sep; 63(9):1424-30. PubMed ID: 24146170
[TBL] [Abstract][Full Text] [Related]
18. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.
Wallach S; Cohen S; Reid DM; Hughes RA; Hosking DJ; Laan RF; Doherty SM; Maricic M; Rosen C; Brown J; Barton I; Chines AA
Calcif Tissue Int; 2000 Oct; 67(4):277-85. PubMed ID: 11000340
[TBL] [Abstract][Full Text] [Related]
19. Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate.
Watts NB; Lindsay R; Li Z; Kasibhatla C; Brown J
Osteoporos Int; 2003 Jun; 14(5):437-41. PubMed ID: 12730756
[TBL] [Abstract][Full Text] [Related]
20. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis.
Harrington JT; Ste-Marie LG; Brandi ML; Civitelli R; Fardellone P; Grauer A; Barton I; Boonen S
Calcif Tissue Int; 2004 Feb; 74(2):129-35. PubMed ID: 14648009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
